- Home
- VRCA vs XOMA Comparison
VRCA vs XOMA Comparison
Compare VRCA & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- XOMA
- Stock Information
- Founded
- VRCA 2013
- XOMA 1981
- Country
- VRCA United States
- XOMA United States
- Employees
- VRCA N/A
- XOMA N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- XOMA Health Care
- Exchange
- VRCA Nasdaq
- XOMA Nasdaq
- Market Cap
- VRCA 363.1M
- XOMA 355.6M
- IPO Year
- VRCA 2018
- XOMA N/A
- Fundamental
- Price
- VRCA $0.75
- XOMA $30.38
- Analyst Decision
- VRCA Buy
- XOMA Strong Buy
- Analyst Count
- VRCA 6
- XOMA 2
- Target Price
- VRCA $7.33
- XOMA $78.50
- AVG Volume (30 Days)
- VRCA 646.5K
- XOMA 19.5K
- Earning Date
- VRCA 11-04-2024
- XOMA 11-07-2024
- Dividend Yield
- VRCA N/A
- XOMA N/A
- EPS Growth
- VRCA N/A
- XOMA N/A
- EPS
- VRCA N/A
- XOMA N/A
- Revenue
- VRCA $9,210,000.00
- XOMA $21,606,000.00
- Revenue This Year
- VRCA $291.12
- XOMA $456.45
- Revenue Next Year
- VRCA $104.31
- XOMA $29.84
- P/E Ratio
- VRCA N/A
- XOMA N/A
- Revenue Growth
- VRCA 187.45
- XOMA 389.82
- 52 Week Low
- VRCA $0.70
- XOMA $14.27
- 52 Week High
- VRCA $11.41
- XOMA $33.78
- Technical
- Relative Strength Index (RSI)
- VRCA 26.09
- XOMA 53.45
- Support Level
- VRCA $1.40
- XOMA $26.74
- Resistance Level
- VRCA $1.74
- XOMA $33.78
- Average True Range (ATR)
- VRCA 0.13
- XOMA 1.56
- MACD
- VRCA -0.06
- XOMA 0.10
- Stochastic Oscillator
- VRCA 0.00
- XOMA 49.15
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.